Expression of Cripto-1 in the placenta and its role in placenta accreta and placenta previa by Jiang, Lingling et al.
86
ORIGINAL PAPER /  OBSTE TRICS
Ginekologia Polska
2019, vol. 90, no. 2, 86–92
Copyright © 2019 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.2019.0015
Corresponding author:
Jianying Yan
Fujian Provincial Maternity and Children’s Hospital, affiliated hospital of Fujian Medical University, Fuzhou, Fujian, China
e-mail: yanjy2004@163.com
Expression of Cripto-1 in the placenta and its role in 
placenta accreta and placenta previa
Lingling Jiang1, Xiaoya Wu2, Jianying Yan1*, Rongxin Chen1, Qing Han1, Qinjian Zhang1
1Fujian Provincial Maternity and Children’s Hospital, affiliated hospital of Fujian Medical University, Fuzhou, Fujian, China 
2Fujian Provincial Hospital, affiliated hospital of Fujian Medical University, Fuzhou, Fujian, China 
*Co-first author: Jianying Yan
ABSTRACT
Objectives: This study Aims to explore the role of placental Cripto-1 in the incidence  of an adherent placenta.
Material and methods: Ten pregnant women with placenta increta, 20 pregnant women with placenta previa and 
30 women with normal pregnant were enrolled in this study. Reverse transcription-polymerase chain reaction (RT-PCR) 
was used to measure the expression of Cripto-1 in the placenta while as the analysis of placental Cripto-1 was performed 
by Western blotting
Results: The placenta increta group showed higher levels of Cripto-1 in the center of the increta as compared to the 
non-implantation area. The level of placental Cripto-1 in the placenta increta was higher than that of the placenta accrete. 
The expression of placental Cripto-1 in the placenta increta and placenta previa groups was higher than that of control. 
Conclusions: Placental Cripto-1 is involved in the regulation of placental tissue invasion. Additionally, excessive placental 
growth or penetration into the myometrium are likely to be involved in the development of placenta increta.  
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INTRODUCTION
Placenta increta (PA) refers to the chorionic villi inva-
sion of the myometrium caused by an abnormal placenta. 
It can be divided into three categories: adhesive placenta, pla-
centa accrete and placenta percreta, according to the depth 
of the invasion. Placenta increta, also referred to as pathologi-
cal placenta adhesion [1], is a serious complication in the field 
of obstetrics. Recent researches on placenta implantation 
especially those exploring risk factors, diagnosis, treatment 
methods, and maternal and fetal outcome are lacking. To 
date, there are few studies on the etiology and pathogenesis 
of placental implantation. The mechanisms responsible for 
placenta accreta are not completely understood. Although 
it is generally accepted that decidual dysplasia, trophoblast 
cell invasion ability enhancement, and vascular remodeling 
may be of importance in elucidating the pathophysiology 
of placenta accreta [2], the mechanisms responsible for its 
occurrence are still not completely understood. Cripto-1 is 
a glycosylphosphatidylinositol-anchored small molecular 
signaling protein and a member of epidermal growth fac-
tors EGF-CFC family. In early embryonic development, Crip-
to-1 plays an important role in germ layer differentiation 
and later in each organ development. It plays a role in the 
activation of multiple signaling pathways regulating tumor 
cell proliferation, differentiation, and migration. Placental 
trophoblast cells and tumor cells have similar biological 
characteristics, and Cripto-1 can control their migration and 
invasion as well. So, we assume that the effect of placental 
trophoblast cells on cell morphology and their ability to 
promote placenta implantation might be an important fac-
tor in the pathogenesis of placenta increta. Higher expres-
sion of Cripto-1 can lead to an increase in cell proliferation, 
migration and invasion, abnormal placenta angiogenesis, 
enhancement of placental trophoblast cell invasive ability, 
and placental invasion. The present study examined the 
levels of Cripto-1 in pregnant women with placenta accreta.
MATERIAL AND METHODS 
Enrolled subjects were pregnant women with regu-
lar antenatal care and hospitalized for cesarean section at 
87
Lingling Jiang et al., Cripto-1 in the placenta and its role
www. journals.viamedica.pl/ginekologia_polska
the Obstetric Department of Fujian Provincial Maternity 
and Children’s Hospital from January to December 2015. 
All subjects were Chinese nationals. Based on clinical mani-
festations, ultrasonic testing, and pathological examination, 
10 cases were identified as placenta accreta (PA) and 20 as pla-
centa previa (PP). An additional thirty pregnant women who 
received cesarean section due to a scarred uterus, abnormal 
fetal position, abnormal obstetric canal, and social factors were 
selected to form the control group (NC). This study referred to 
the relevant literature [3] for the diagnostic criteria of PP and 
PA. Late pregnancy is defined as 28 weeks or later. Those with 
both PP and PA were included in the PA group. No included 
subject underwent labor and nor had a premature rupture of 
membranes at the time of cesarean section. None of the wom-
en were in active labor, had rupture of fetal membranes, or had 
clinical signs of infection. Patients with pregnancy complica-
tions and surgical complications were excluded from the study. 
All subjects had a single pregnancy. Informed consents were 
obtained from each subject, and the protocol for this study 
was approved by the local Institutional Review Board (Eth-
ics committee of Fujian provincial maternal and child health 
hospital, 20140928). 
Specimen collection
Immediately after cesarean section, the placental tissues 
were taken aseptically from the maternal surface of the pla-
centa. Specific sites of sample collection in each group are 
described as follows: samples were collected from an accreta 
area and a none-accreta area for the PA group whereas for 
the PP group, placental tissues were collected from a mar-
ginal location and a central location. For the normal group, 
placental tissues were only collected from the central area. 
Tissue samples were incised at 1.0×1.0×1.0 cm under sterile 
conditions. Sites with hemorrhage, necrosis, and calcifica-
tion were avoided. After rinsing with cold saline, placental 
samples were immediately put into a 1.5 mL EP tube, frozen 
in liquid nitrogen and subsequently transferred into sterile 
tubes for storage at -70°C until assayed. Repeated freezing 
and thawing were avoided.
Main materials
The real-time fluorescence quantification PCR assay was 
purchased from Applied Biosystems (ABI), while nucleic 
acid and protein quantitative determination apparatus, and 
low-temperature high-speed centrifugal machine were from 
Thermo. The horizontal nucleic acid electrophoresis appa-
ratus was from the Beijing Liuyi Biotechnology Co., Ltd. The 
gel-imaging scanner was from BIO-Rad, USA. The rabbit an-
ti-human Cripto-1 monoclonal antibody was purchased from 
Abcam. The rabbit anti-human GAPDH polyclonal antibody, 
horseradish peroxidase-conjugated anti-rabbit secondary 
antibody, and high-sensitivity chemiluminescence assay kit 
were from Kangwei Shiji Biotechnology Company, Beijing. The 
PCR primers were from Beijing Dingguo Changsheng Biotech-
nology company and SYBR Green I (10x) was from Genview.
Immunohistochemistry
After dehydration and paraffin embedding, tissues were 
sliced into 3μm thick sections and adsorbed on adhesion 
slides for hot repair (88°C for 10 min). The slides were de-
waxed, hydrated with graded ethanol and immersed in 
sodium citrate solution under high-temperature conditions 
for 1–2 min for antigen repair. After cooling, the slides were 
washed with Tris-buffered saline (TBS). A 30% hydrogen per-
oxide solution was used to block endogenous peroxidase for 
10 min followed by incubation with sheep serum for 30 min 
at room temperature and binding with the nonspecific an-
tibody. Monoclonal mouse anti-human antibodies against 
Cripto-1 (Abcam, USA) were added to the slides at a dilution 
of 1:100 and incubated at 4°C overnight. Biotinylated rabbit 
anti-mouse antibody (Abcam, USA) was used at a dilution of 
1:100 for 30 min at room temperature. After washing with 
TBS, the specimens were stained with diaminobenzidine, 
and hematoxylin and coverslipped for microscopic obser-
vation. Phosphate buffer solution instead of the primary 
antibody was used as a negative control.
Western blot 
Tissue samples were first washed with PBS three times 
then washed with lymphocyte lysis buffer. Proteins were 
purified with the addition of the extraction buffer. Protein 
concentration was measured by the BCA assay. According to 
the results of the protein quantification, the corresponding 
volume of total protein and 5x protein gel electrophoresis 
buffer were mixed and the protein denatured for 10 min at 
95°C. The gel was pre-electrophoresed for 10 min at a con-
stant 80V until the leading edge of the bromophenol blue 
reached the separation gel. The voltage was adjusted to 
provide a constant 120V until the dye reached the bottom of 
the separation gel. The protein was transferred at a constant 
110 V for 1 h. Membranes were blocked for two hours at room 
temperature in Tris-buffered saline-Tween-20 (TBS-T) con-
taining 10% skimmed milk. Membranes were then incubated 
overnight with the appropriate primary antibody (a rabbit 
monoclonal antibody against Cripto-1, Abcam Company, UK) 
diluted in TBS-T with 3% BSA at 4°C. Membranes were then 
incubated with secondary antibodies (an anti-rabbit IgG 
antibody, Beijing Dingguo Changsheng Biotechnology Com-
pany, China) for one hour at room temperature after washing 
with TBS-T. Blots were washed three times with TBS-T, and the 
detection was performed using the BM Chemiluminescence 
system. After exposure, membranes were stained with Amido 
Black Staining Solution to calculate variations in protein 
content among samples. Densitometric analysis of band 
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intensities was made with Basic Quantifier software. β-actin 
was used as a loading control. We compared the gray values 
of the Cripto-1 and β-actin protein bands.
RTQ-PCR 
 Trizol was used to extract total RNA from placental tis-
sues. A spectrophotometer was used to measure the light 
absorption values (A), and total RNA concentration and pu-
rity were calculated from 260 nm and 280 n absorption. RNA 
integrity was determined by 1% agarose gel electrophore-
sis. A sample of 2ug of total RNA was reverse transcribed into 
cDNA. Real-time fluorescence quantification PCR was used 
for quantitative determination. The full-length sequence 
of the target gene mRNA was obtained from GenBank. 
Primer 5.0 was used to design the primer sequence. After 
Blast analysis, the primer sequence was shown to have the 
necessary specificity. This study entrusted Beijing Dingguo 
Changsheng Biotechnology Co., Ltd. to synthesize all the 
primers. β-actin: The upstream primer is 5’-ATC ATG TTT GAG 
ACC TTC AAC A-3’, while the downstream primer is 5’-CAT 
CTC TTG CTG AAG ECC A-3’. Cripto-1: The upstream primer is 
5’-CAG GGA GAC TGG GTA GGA A-3’, while the downstream 
primer is 5’- TGT TGG GGA CAT TGA GGT A-3’. The RT-PCR 
reaction conditions and procedures were performed accord-
ing to the instructions, and 2－△△CT was used to conduct 
a relative quantitative analysis of the results.
Statistical analysis 
 Statistical analysis was carried out with the Statistical 
Package for Social Science Software (SPSS19.0). Data are 
presented as mean ± SD. Differences among groups were 
compared with one-way ANOVA. Comparison between two 
groups was performed with t-test or Wilcoxon and Kruskal 
Wallis tests, while comparison among the three groups 
was performed with one-way ANOVA. A P-value < 0.05 was 
regarded as statistically significant.
RESULTS
Baseline characteristics of subjects from the 
three groups
The differences in age and number of cesarean sections 
between patients in the groups were not statistically signifi-
cant. The number of pregnancies, hospital stays, duration of 
operation, intraoperative hemorrhage, and hospitalization 
costs of the PA group were significantly higher than those of 
the Control group, (P < 0.05). Gestational age, the placenta 
weight, and weight of the infant in both the PA and PP 
groups were significantly lower than those of the Control 
group (P < 0.05) (Tab. 1, 2).
The emergency admission rates of the PA group, PP 
group, and the Control group were 80%, 45%, and 16.7%, 
respectively. Meanwhile, the ICU admission rates of the 
mothers were 80% for the PA group, 75% for the PP group 
and 0% for the Control group. The NICU admission rates of 
newborns were 30%, 30%, and 0%, respectively. (Fig. 1).
Table 1. Comparison of the clinical situations of the three groups of pregnant women
Group No. of Cases Age (Y) Gestational Weeks (Week)
Number of Pregnancies 
(Times)
Number of Uterine 
Surgeries (Times) Hospital Stay (Day)
PA 10 31.7 ± 6.6 35.3 ± 4.0* 2.7 ± 1.8* 0.7 ± 0.7 8.0 ± 4.3*
PP 20 30.3 ± 5.8 36.2 ± 2.5* 1.5 ± 1.5 0.4 ± 0.8 6.5 ± 2.9
CON 30 30.2 ± 3.8 39.2 ± 1.0 1.0 ± 0.8 0.5 ± 0.6 5.4 ± 1.7
* P < 0.05
Table 2. Comparison of the clinical situations of the three groups of pregnant women
Group Duration of Operation (Hour)
Intraoperative 
Hemorrhage (ML) Placental Weight (G) Weight of Newborn (G)
Hospitalization Costs 
(in RMB 10,000)
PA 1.6 ± 1.0* 1280.0 ± 1316.9* 511.0 ± 147.8* 2441 ± 913.7* 2.2 ± 1.6*
PP 0.9 ± 0.3 543 ± 179.7 577.8 ± 106.5* 2651.1 ± 644.7* 1.2 ± 0.3
CON 0.9 ± 0.3 383.3 ± 130.9 673.6 ± 147.3 3368.8 ± 528.6 0.9 ± 0.1
* P < 0.05
Emergent admission
rates
ICU admission rates
of mothers
NICU admission rates
of newborns
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
80% 80%
75%
0 0
45%
16.70%
30%30%
PA Group      PP Group     Control Group
Figure 1. Analysis of hospitalization
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Cripto-1 expression levels in placental tissues of 
the three groups
Localization of Cripto-1 in the placenta
Immunohistochemistry indicated the presence of Crip-
to-1 in placental tissues of subjects from the three groups. The 
expressions of Cripto-1 in placental tissues of PA and PP groups 
were higher than that of the control group. Positive staining 
showed brown yellow granules within the tissue (Fig. 2).
Cripto-1 expression levels in placental tissues of the 
three groups
The ratios of Cripto-1 protein gray value/β-actin protein 
gray value of the three groups were: PA group 1.054 ± 0.178, PP 
group 0.774 ± 0.170, and the Control group 0.369 ± 0.110. The 
relative content of Cripto-1 protein in the PA and PP groups 
were significantly higher than that of the Control group 
(P < 0.05). The Cripto-1 protein level in the PA group was 
much higher than that of PP group (P < 0.05). (Fig. 3).
Cripto-1 expression at different sites in the PA group
There was a significant difference in average levels of 
Cripto-1 protein between samples from the accreta area 
1.206 ± 0.038 and the none-accreta area 0.901 ± 0.119 in the 
Figure 2. Expression and distribution of Cripto-1 in placental tissue 
A — negative control (100x); B — showed the expression of Cripto-1 in placenta tissues in group PA (100x); C — showed the expression of Cripto-1 
in placenta tissues in group PA (100x). It was positive for cytoplasmic brown staining
CBA
Figure 3. Cripto-1 expression of the pregnant women of the three 
groups
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Figure 4. Cripto-1 expression of different sites of PA Group
PA group. The relative content of Cripto-1 mRNA in the PA 
group was 7.971 ± 1.751 at the central area and 4.520 ± 0.852 
at the none-accreta area. The difference between the two 
sites was statistically significant (P < 0.05). (Fig. 4).
Cripto-1 expression at different sites in the PP group 
and the Control group
The relative content of Cripto-1 protein in the PP group was 
0.739 ± 0.136 at the central area and 0.810 ± 0.196 at the edge. 
The difference between the two sites was not statistically sig-
nificant. No significant difference in the relative content of Crip-
to-1 protein was seen between the central area (0.368 ± 0.112) 
and the edge (0.370 ± 0.110) in the Control group.
The relative content of Cripto-1 mRNA in the PP group 
was 3.680 ± 2.227 at the central area and 4.262 ± 2.227 at the 
edge. The difference between the two sites was not statisti-
cally significant. The relative content of Cripto-1 mRNA in 
the Control group was 3.045 ± 1.447 at the central area and 
3.030 ± 1.411 at the edge. The difference between the two 
sites was not statistically significant. (Fig. 5).
Cripto-1 expression in different types of accreta
In the PA group, the Cripto-1 expression levels were 
significantly higher in the placenta increta (PI) tissues than in 
the placenta accreta (P < 0.05). (Tab. 3, Fig. 6).
  DISCUSSION
Placenta accreta is a serious obstetric complication. The 
recent years have seen a sharp increase in its incidence with 
the increase in uterine surgeries like cesarean section and 
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abortion. China reports that the morbidity from placental 
accreta has reached 0.4% domestically [4]. Its clinical mani-
festations include spontaneous uterine perforation during 
pregnancy and no, or partial, separation of the placenta 
during delivery. These can lead to life-threatening compli-
cations such as hemorrhage, shock, secondary infection, 
or even death during childbirth. It is reported that the rate 
of hysterectomy caused by PA has reached 77.8% currently 
making PA a leading cause of hysterectomy due to massive 
bleeding [5]. The mortality rate of pregnant women due to 
PA has reached 7%. The clinical data of this study indicate 
that the gestational age at delivery in the PA group is lower 
than that of the Control group. Additionally, the length of 
hospitalization, the duration of operation, the occurrence 
of intraoperative hemorrhage, hospitalization costs, emer-
gency admission rate, and ICU admission rate are also higher 
in the PA group. Newborns in the PA group have been shown 
to have a lower birth weight, a higher NICU admission rate, 
and premature birth rate. Comparison within the emer-
gency admission cases has shown that planned delivery 
can reduce the amount of bleeding, the incidence of other 
complications, and the length of an ICU stay. PA not only 
represents a serious health threat to mother and child but 
also increases the costs of medical services and is a great 
economic burden on families.
At present, the etiology of PA is still not fully understood, 
and multiple factors are implicated in its pathogenesis. It is 
of tremendous significance to be able to clarify its patho-
genesis, develop early detection means and interventional 
methods to avoid its complications. Recent research has 
indicated that decidual maldevelopment, enhanced tropho-
blast invasion, and abnormal vascular remodeling may be 
important causes [6].
The results of this study found that, compared with the 
Control group, the PA group had higher expressions levels of 
Cripto-1. Moreover, the expression levels varied by anatomic 
sites. Cripto-1 expression level at the central area is much 
higher than that in the none-accreta area. This is indicative 
of enhancement of trophoblast invasion and excessive pla-
cental invasion. The PP group also showed higher levels of 
Cripto-1 expression when compared to the Control group. 
However, the difference between Cripto-1 expressions in the 
central site and the edge in the PP group is not statistically 
significant. Excessive trophoblast invasion was not observed 
in the PP group even though Cripto-1 expressions varied 
according to the sampling site. This might be due to lower 
Cripto-1 expressions in the PP group as compared to the PA 
group. The cell signal intensity was low and did not reach 
the threshold of excessive trophoblast invasion in the PP 
group. There is also the possibility that the up-regulation 
of Cripto-1 expression is only one of the conditions for the 
enhancement of trophoblast invasion. There are other vital 
factors to be explored that might affect excessive tropho-
blast invasion. Only two cases of placenta accreta were 
collected in this study. Western-blot results indicated that 
Cripto-1 expression levels in placental tissues are signifi-
cantly higher in subjects with placenta increta than those 
with placenta accreta.
During normal pregnancy, trophoblast cells shift from 
epithelial phenotype to mesenchymal phenotype via EMT 
and differentiate into extravillous trophoblast cells with 
strong invasive ability. The EVTS migrate to the uterine de-
cidua, infiltrating along the maternal spiral artery in a ret-
rograde direction, gradually replacing vascular endothelial 
cells, and transforming into non-invasive cell phenotypes 
like endothelial trophoblasts and myometrial multinuclear 
giant cells via MET. During a normal pregnancy, the invasive 
ability of trophoblast cells is confined within a certain time 
and space. Therefore, the invasion is limited in depth.
Table 3. Cripto-1 expression of different accreta types
Group Western-blot RT-PCR
Placenta increta (n = 8) 1.071 ± 0.219 6.676 ± 2.224
Placenta accreta (n = 2) 0.984 ± 0.170 4.523 ± 1.250
Figure 6. Cripto-1 expression of different accreta
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The Cripto-1 gene was first found and separated by Cic-
codicola et al. in the human teratoma NTERA2/D1 cell line 
cDNA library in 1989 [7]. Cripto-1 is expressed at a higher 
level during early embryonic development but is weakly 
expressed or not detected in the placenta in the second and 
the third trimesters of normal pregnancy. The up-regulation 
of Cripto-1 may destroy normal EMT and MET regulatory 
mechanisms of trophoblast cells and activate abnormal 
signal pathways to strengthen the duration and intensity 
of trophoblast invasion.
Consistent with other studies, the results of this study 
indicate that the expression levels of Cripto-1 protein and 
mRNA in both the PA and PP groups are higher than in the 
Control group. Bandeira et al. [8] adopted an immunohisto-
chemical technique to determine the Cripto-1 expression in 
the placenta during the third trimester of pregnancy. They 
have reported that Cripto-1 expression in the PA group was 
significantly higher than in the Control group and that the 
expression level increases along with the depth of accreta. 
Additionally, they have put forward for the first time the 
idea that EVT is the main cell expressing Cripto-1 and that 
With the morphological changes of EVT at the site of ac-
creta, trophoblast cells clustered together clone-like or were 
dispersedly distributed. They have exhibited a greater cell 
volume with scattered cells showing migrational characteris-
tics and a star-shaped cytoplasm or the presence of long-axis 
protrusions. The number of multinucleated giant cells in the 
myometrium was significantly reduced. Kim et al. [9] found 
that the thickness of the ETV cell layer in the accreta area was 
significantly higher than that of a normal placenta. In the third 
trimester of normal pregnancy, EVT cells showed no prolifera-
tive activity and demonstrated a low apoptotic index. Moreo-
ver, the differentiation of many multinuclear giant cells from 
trophoblast cells at their final stage was detected. Trophoblast 
cells invading the myometrium and expressing high levels 
of Cripto-1 in EVT is consistent with Cripto-1 promoting the 
migration and invasion of trophoblast cells.
A high-level of expression of Cripto-1 may mediate 
several mechanisms thus enhancing the invasive ability of 
trophoblast cells and participating in the pathogenesis of 
placenta accreta. The increased expression of Cripto-1 in 
trophoblast cells may interact with the ability of the TGF-β 
family to regulate classic EMT transcription factors. The 
transcription and translation of Snail, Twist, and Slug will 
promote EMT [10]. In contrast, for PA, the EMT of trophoblast 
cells does not develop toward tumor formation. There may 
be a complex regulatory network that limits EMT within 
a controllable range. The wnt/β-catenin signaling pathway 
plays a crucial role in promoting the migration and invasion 
of trophoblast cells. In the Cripto-1 gene promoter area, 
there is a binding area for T-cell factor/lymphoid enhancer 
factor (Tcf/Lef ) which is regulated by the Wnt/β-catenin sig-
nal pathway. Up-regulated Cripto-1 can also serve as a Wnt 
11 co-receptor in the cell membrane and, together with 
Glypican-4 and Frizzled 7, activate β-catenin. The β-catenin 
in the cytoplasm can enter into the nucleus and, as a coac-
tivator of specific DNA-binding protein transcription in the 
nucleus, upregulate Cripto-1 expression but also regulate 
the expression of c-Myc and cyclin D1 (factors related to 
cell adhesion and cell morphological changes). The mi-
gration and invasion of the EVTS are enhanced through 
a complex cell regulatory network and interaction with ex-
pressed factors. Previous studies have found that E-cadherin 
participates in placenta accreta by regulating trophoblast 
invasion [11]. Cripto-1 activates the Wnt/β-catenin signal 
pathway, reduces free β-catenin in the cytoplasm, affects 
the interaction between β-catenin and E-cadherin as well 
as the number and stability of cadherin-catenin complexes, 
a connecting structure of cell adhesion, and increases cell 
migration and invasion. 
Cripto-1 promotes the differentiation of HUVECs into 
vascular-like structures in vitro and increases the microvessel 
density of MCF-7 tumors in nude mice [12]. Furthermore, 
by regulating a specific signaling pathway, it can promote 
vascular remodeling and neovascularization in PA. Members 
of the Cripto family can interact with glucose regulatory 
protein 78, promoting the activation of both TGF-beta and 
Src/MAPK/PI3K signaling pathways. Its downstream signal-
ing molecules TGF-beta, a bone morphogenetic protein, and 
Akt are involved in the regulation of natural killer cells and 
Sertoli cell differentiation [13]. Natural killer cells infiltrate the 
decidual tissue and promote abnormal vascular remodeling 
by regulating trophoblast cells which in turn invade the uter-
us to replace the endothelial cells and the membrane integ-
rity of the uterine spiral artery [14]. MMPs also play a crucial 
role in vascular remodeling. Cripto-1 promotes MMP2 pro-
duction via the TGF-beta body/Cripto-1/Smad2 signaling 
pathway [15]. Cripto-1 participation in placenta increta may 
be through vascular remodeling.
CONCLUSIONS
In summary, the pathogenesis of placenta accreta may 
include decidua maldevelopment, enhanced trophoblast in-
vasion, and abnormal vascular remodeling. Upregulation of 
Cripto-1 expression strengthens trophoblast invasion. Exces-
sive placental invasion may penetrate the myometrium and 
lead to the development of placenta accreta. Therefore, the role 
of Cripto-1 in the promotion of vascularization during the de-
velopment of placenta accreta is worth being further explored.
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